Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that
occurs either as a predictable event when an individual is exposed to toxic doses of some …

Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver
disorders faced by hepatologists, because of the myriad of drugs used in clinical practice …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint
molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies …

Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …

The application of immune checkpoint inhibitors (ICI) in advanced cancer has been a major
development in the last decade. The indications for ICIs are constantly expanding into new …

Immune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several
types of cancer. However, due to their mode of action, these treatments are associated with …

In recent years, cancer immunotherapy has made remarkable achievements. Immune
checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the …

Background & Aims Immune checkpoint inhibitors (ICIs) have changed the landscape of
cancer therapy. Liver toxicity occurs in up to 25% of patients treated with ICIs. The aim of our …

ABSTRACT Introduction: Immune checkpoint inhibitors (ICIs) block cytotoxic T lymphocyte
antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) …